CN110088283A - 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法 - Google Patents

通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法 Download PDF

Info

Publication number
CN110088283A
CN110088283A CN201780077941.7A CN201780077941A CN110088283A CN 110088283 A CN110088283 A CN 110088283A CN 201780077941 A CN201780077941 A CN 201780077941A CN 110088283 A CN110088283 A CN 110088283A
Authority
CN
China
Prior art keywords
days
rnai agent
day
months
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780077941.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·韦恩加德
D·卡伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60388127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110088283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicines Co filed Critical Medicines Co
Priority to CN202411482008.6A priority Critical patent/CN119700800A/zh
Priority to CN202411479127.6A priority patent/CN119318663A/zh
Priority to CN202411481996.2A priority patent/CN119345221A/zh
Publication of CN110088283A publication Critical patent/CN110088283A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780077941.7A 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法 Withdrawn CN110088283A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202411482008.6A CN119700800A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)蛋白质预防心血管事件的方法
CN202411479127.6A CN119318663A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法
CN202411481996.2A CN119345221A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US62/409,816 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US62/422,028 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US62/472,525 2017-03-16
US201762550426P 2017-08-25 2017-08-25
US62/550,426 2017-08-25
PCT/US2017/057218 WO2018075658A1 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202411481996.2A Division CN119345221A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法
CN202411482008.6A Division CN119700800A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)蛋白质预防心血管事件的方法
CN202411479127.6A Division CN119318663A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法

Publications (1)

Publication Number Publication Date
CN110088283A true CN110088283A (zh) 2019-08-02

Family

ID=60388127

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780077941.7A Withdrawn CN110088283A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法
CN202411482008.6A Pending CN119700800A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)蛋白质预防心血管事件的方法
CN202411481996.2A Pending CN119345221A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法
CN202411479127.6A Pending CN119318663A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411482008.6A Pending CN119700800A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)蛋白质预防心血管事件的方法
CN202411481996.2A Pending CN119345221A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法
CN202411479127.6A Pending CN119318663A (zh) 2016-10-18 2017-10-18 通过降低前蛋白转化酶枯草杆菌蛋白酶Kexin 9(PCSK9)蛋白质预防心血管事件的方法

Country Status (21)

Country Link
US (3) US20180104360A1 (https=)
EP (2) EP4397311A3 (https=)
JP (4) JP7181881B2 (https=)
KR (3) KR20250171391A (https=)
CN (4) CN110088283A (https=)
AU (2) AU2017346879B2 (https=)
CA (1) CA3042423A1 (https=)
CL (1) CL2019001047A1 (https=)
DK (1) DK3529360T3 (https=)
ES (1) ES2982911T3 (https=)
FI (1) FI3529360T3 (https=)
HR (1) HRP20240930T1 (https=)
HU (1) HUE067712T2 (https=)
IL (1) IL266066A (https=)
LT (1) LT3529360T (https=)
MX (2) MX2019004573A (https=)
PL (1) PL3529360T3 (https=)
PT (1) PT3529360T (https=)
RS (1) RS65725B1 (https=)
SI (1) SI3529360T1 (https=)
WO (1) WO2018075658A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061157A1 (en) * 2022-09-19 2024-03-28 Kylonova (Xiamen) Biopharma Co., Ltd. Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292159B1 (en) 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
CN108348541A (zh) 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
EP4397311A3 (en) 2016-10-18 2024-10-16 Novartis AG Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN115066498A (zh) 2020-03-16 2022-09-16 阿尔戈诺特Rna有限公司 Pcsk9的拮抗剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089313A1 (en) * 2012-12-05 2014-06-12 Alnylam Pharmaceuticals PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
CN108348541A (zh) * 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
EP4397311A3 (en) 2016-10-18 2024-10-16 Novartis AG Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089313A1 (en) * 2012-12-05 2014-06-12 Alnylam Pharmaceuticals PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAMES M MCKENNEY: "Understanding PCSK9 and anti-PCSK9 therapies", 《OURNAL OF CLINICAL LIPIDOLOGY》 *
RICARDO LADEIRAS-LOPES等: "Atherosclerosis: Recent trials, new targets and future directions", 《INTERNATIONAL JOURNAL OF CARDIOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061157A1 (en) * 2022-09-19 2024-03-28 Kylonova (Xiamen) Biopharma Co., Ltd. Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications

Also Published As

Publication number Publication date
JP2025016469A (ja) 2025-02-04
WO2018075658A1 (en) 2018-04-26
JP2026062719A (ja) 2026-04-10
HRP20240930T1 (hr) 2024-10-11
CN119700800A (zh) 2025-03-28
DK3529360T3 (da) 2024-07-15
JP7566815B2 (ja) 2024-10-15
SI3529360T1 (sl) 2024-08-30
AU2017346879B2 (en) 2023-11-30
HUE067712T2 (hu) 2024-11-28
CN119345221A (zh) 2025-01-24
US20260108631A1 (en) 2026-04-23
LT3529360T (lt) 2024-07-25
EP3529360A1 (en) 2019-08-28
AU2023263519A1 (en) 2023-12-07
EP4397311A2 (en) 2024-07-10
JP7181881B2 (ja) 2022-12-01
AU2017346879A1 (en) 2019-05-23
RS65725B1 (sr) 2024-08-30
KR20240067272A (ko) 2024-05-16
AU2023263519B2 (en) 2026-02-12
CN119318663A (zh) 2025-01-17
PL3529360T3 (pl) 2024-08-26
US20210093736A1 (en) 2021-04-01
MX2024004495A (es) 2024-05-08
ES2982911T3 (es) 2024-10-18
CL2019001047A1 (es) 2020-05-08
IL266066A (en) 2019-06-30
BR112019007843A2 (pt) 2019-10-01
KR20190077411A (ko) 2019-07-03
CA3042423A1 (en) 2018-04-26
MX2019004573A (es) 2019-10-07
KR20250171391A (ko) 2025-12-08
EP3529360B1 (en) 2024-04-17
JP2022109948A (ja) 2022-07-28
PT3529360T (pt) 2024-07-12
EP4397311A3 (en) 2024-10-16
US20180104360A1 (en) 2018-04-19
JP7850215B2 (ja) 2026-04-22
FI3529360T3 (fi) 2024-07-11
JP2019531357A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7566815B2 (ja) プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
Campbell Long-term neprilysin inhibition—implications for ARNIs
JP5964821B2 (ja) 痛風と高尿酸血症の処置
US11680266B2 (en) Endomucin inhibitor as an anti-angiogenic agent
CN105008394A (zh) 治疗结肠直肠癌的方法
JP2026021335A (ja) ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
HK40113597A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
BR112019007843B1 (pt) Métodos para prevenção de eventos cardiovasculares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
EA040947B1 (ru) Способы профилактики явлений со стороны сердечно-сосудистой системы посредством снижения содержания белка пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
HK40013430B (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
HK40013430A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
TW202434264A (zh) 降低一級預防受試者中重大不良心血管事件風險之方法
KR20250108710A (ko) 다발성 경화증의 치료 방법
CN121693519A (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
NZ792465A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231018

Address after: Basel, SUI

Applicant after: NOVARTIS AG

Address before: New Jersey USA

Applicant before: THE MEDICINES Co.

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190802